Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
46 Results for "
Deruxtecan
" in MedChemExpress (MCE) Product Catalog:
Products (46)
46 Results for "Deruxtecan" in MCE Product Catalog:
32
32 Publications Verification
Synonyms: MC-GGFG-DXD
Target:
Research Areas:
Deruxtecan is an ADC drug-linker conjugate composed of an DX-8951 derivative (DXd) and a maleimide-GGFG peptide linker, used for synthesizing Trastuzumab deruxtecan (HY-138298A) and Patritumab deruxtecan (HY-P99813) .
9
9 Cited Publications
Synonyms: T-DXd; DS-8201; DS-8201a
9
9 Cited Publications
Synonyms: T-DXd (solution); DS-8201 (solution); DS-8201a (solution)
2
2 Cited Publications
Synonyms: DS-1062 (solution); Dato-DXd (solution)
2
2 Cited Publications
Cat. No.: HY-P99843
CAS No.: 2267989-53-5
Target:
Research Areas:
2
Research Areas:
Datopotamab deruxtecan (DS-1062) is a TROP2-targeted antibody-drug conjugate (ADC) with human TROP2 Kd of 0.74 nmol/L. Datopotamab deruxtecan consists of the antibody Datopotamab (HY-P99843) and the toxic molecule-linker conjugate Deruxtecan (HY-13631E). Datopotamab deruxtecan binds TROP2, triggers internalization and lysosomal trafficking and releases DXd topoisomerase I inhibitor payload. Datopotamab deruxtecan disrupts DNA function, induces DNA damage, apoptosis, and bystander killing of tumor microenvironment cells. Datopotamab deruxtecan can be used in research related to triple-negative breast cancer, gastric cancer, and non-small cell lung cancer .
1
Target:
Research Areas:
Patritumab deruxtecan (HER3-DXd) is an antibody-drug conjugate (ADC) targeting HER3, consisting of the anti-HER3 IgG1 antibody Patritumab (HY-P99275), a cleavable tetrapeptide linker, and the membrane-permeable topoisomerase I (Topoisomerase Ⅰ) inhibitor DXd (HY-13631D). After binding to membrane-localized HER3, Patritumab deruxtecan is internalized into lysosomes, where the linker is cleaved to release DXd. DXd enters the nucleus to induce DNA damage and cell death, and exerts a bystander effect via transmembrane diffusion. Patritumab deruxtecan reduces the viability of HER3-positive cells and induces features of immunogenic cell death including CALR membrane exposure, ATP and HMGB1 release, and can be used in studies related to HER3-positive breast cancer and non-small cell lung cancer .
1
1 Cited Publications
Cat. No.: HY-164152A
1
1 Cited Publications
Cat. No.: HY-164152
Research Areas:
Cat. No.: HY-P3371
CAS No.: 2484870-92-8
Synonyms: DS-7300a; MABX-9001a; I-DXd
Research Areas:
Research Areas:
Gly-Mal-GGFG-Deruxtecan 2-hydroxypropanamide is the drug-linker conjugate for ADC, containing ADC linker Gly-Mal-GGFG and ADC cytotoxin Deruxtecan 2-hydroxypropanamide .
Cat. No.: HY-164702
Synonyms: Izalontamab Brengitecan
Research Areas:
BL-B01D1 (Izalontamab Brengitecan) is a bispecific antibody-drug conjugate (ADC) targeting EGFR and HER3, formed by conjugating the EGFR/HER3 bispecific antibody Izalontamab (HY-P99676) to a novel TOP-I inhibitor payload Deruxtecan 2-hydroxypropanamide (HY-153891) via a cleavable linker (Mc-Gly-Gly-Phe-Gly). BL-B01D1 binds to EGFR and HER3 on the surface of tumor cells, mediates endocytosis and releases the payload, inhibits topoisomerase I, blocks DNA replication and RNA synthesis, and disrupts DNA structure. BL-B01D1 induces cell cycle S-phase arrest, apoptosis, antibody-dependent cell-mediated cytotoxicity, and tumor cell death. BL-B01D1 can be used for cancer research .
Target:
Research Areas:
Deruxtecan 2-hydroxypropanamide is a highly stable Deruxtecan (HY-13631E) analog that specifically binds to receptors highly expressed in tumor cells .
Cat. No.: HY-164734
CAS No.: 2610074-57-0
Synonyms: R-DXd; DS-6000
Target:
Research Areas:
Raludotatug Deruxtecan is an antibody-drug conjugate targeting CDH6, with an EC50 of 64.7 ng/mL in humans, 70.4 ng/mL in cynomolgus monkeys, and 228 ng/mL in mice. Raludotatug Deruxtecan specifically binds to CDH6 on the surface of cancer cells, triggers lysosomal internalization, and releases the DXd payload that inhibits TOP1. Raludotatug Deruxtecan induces DNA damage, Chk1 phosphorylation, caspase-3 cleavage, apoptosis, and bystander cell death. Raludotatug Deruxtecan is applicable to research related to serous ovarian cancer and renal cell carcinoma .
Cat. No.: HY-P990028
CAS No.: 2610074-56-9
Research Areas:
Cat. No.: HY-45672
CAS No.: 1599440-20-6
Target:
Research Areas:
Gly-Gly-Phe-Gly-NH-CH2-O-CH2COOH is an ADC Linker that can be used to synthesize Drug-Linker Conjugates for ADC. Especially for the synthesis of Deruxtecan (HY-13631E), a toxic drug-linker conjugate .
Cat. No.: HY-177442
Synonyms: DS-3939
Cat. No.: HY-13631EG
CAS No.: 1599440-13-7
Synonyms: MC-GGFG-DXD (GMP)
Cat. No.: HY-13631ES4
Synonyms: MC-GGFG-DXD-d5
Cat. No.: HY-164835
CAS No.: 2760408-75-9
Synonyms: VcMMAE-(PAB-GGFG-AMAA)Exatecan; SMP-54418
Research Areas:
VcMMAE-Deruxtecan (VcMMAE-(PAB-GGFG-AMAA)Exatecan; SMP-54418) is a drug-linker conjugate for ADC, composed of linker-payload molecule conjugate VcMMAE (HY-15575) and linker-payload molecule conjugate Deruxtecan (PAB-GGFG-AMAA)Exatecan) (HY-13631E). VcMMAE-Deruxtecan can be used in the synthesis of ADCs.
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
